Abstract: Disclosed herein are crystalline forms of compounds for the inhibition of RhoGTPase. Also disclosed herein are compounds, pharmaceutical compositions, and methods of treatment of RhoGTPase-mediated diseases, such as hyperproliferative and neoplastic diseases.
Type:
Grant
Filed:
October 5, 2022
Date of Patent:
January 28, 2025
Assignee:
MBQ Pharma
Inventors:
Jocelyn M. Jiménez Cruz, Vilmalí López-Mejías, Torsten Stelzer